众生药业(002317.SZ)昂拉地韦片通过谈判纳入《国家医保目录》

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has successfully included its innovative drug, Anladiwei Tablets (brand name: Anruiwei), in the National Medical Insurance Directory for 2025, which is expected to enhance patient access to effective treatment for influenza [1] Group 1: Product Inclusion - Anladiwei Tablets is the first global drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for the treatment of uncomplicated influenza in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a significant option for patients suffering from influenza [1] - Other core products of the company, including Lai Ru Te Wei Tablets and various formulations, continue to be included in the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of Anladiwei Tablets in the Class B category of the National Medical Insurance Directory is expected to benefit a larger patient population, offering economical, safe, and accessible medication options [1] - The drug was approved by the National Medical Products Administration in May 2025, marking a significant milestone for the company's respiratory pipeline [1]